These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36764998)

  • 1. The modulation of iron metabolism affects the Rhabdomyosarcoma tumor growth in vitro and in vivo.
    Asperti M; Cantamessa L; Gryzik M; Bugatti M; Codenotti S; Denardo A; Vermi W; Fanzani A; Poli M
    Clin Exp Med; 2023 Oct; 23(6):2487-2502. PubMed ID: 36764998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, in vitro and in vivo, the alveolar phenotype subtype.
    Rossetti A; Petragnano F; Milazzo L; Vulcano F; Macioce G; Codenotti S; Cassandri M; Pomella S; Cicchetti F; Fasciani I; Antinozzi C; Di Luigi L; Festuccia C; De Felice F; Vergine M; Fanzani A; Rota R; Maggio R; Polimeni A; Tombolini V; Gravina GL; Marampon F
    Int J Radiat Biol; 2021; 97(7):943-957. PubMed ID: 33979259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell growth potential drives ferroptosis susceptibility in rhabdomyosarcoma and myoblast cell lines.
    Codenotti S; Poli M; Asperti M; Zizioli D; Marampon F; Fanzani A
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1717-1730. PubMed ID: 29971532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumour effects of SFX-01 molecule in combination with ionizing radiation in preclinical and in vivo models of rhabdomyosarcoma.
    Camero S; Milazzo L; Vulcano F; Ceccarelli F; Pontecorvi P; Pedini F; Rossetti A; Scialis ES; Gerini G; Cece F; Pomella S; Cassandri M; Porrazzo A; Romano E; Festuccia C; Gravina GL; Ceccarelli S; Rota R; Lotti LV; Midulla F; Angeloni A; Marchese C; Marampon F; Megiorni F
    BMC Cancer; 2024 Jul; 24(1):814. PubMed ID: 38977944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound.
    Cen L; Hsieh FC; Lin HJ; Chen CS; Qualman SJ; Lin J
    Br J Cancer; 2007 Sep; 97(6):785-91. PubMed ID: 17848913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anti-tumor growth effect of a novel agent DMAMCL in rhabdomyosarcoma in vitro and in vivo.
    Xu N; Hua Z; Ba G; Zhang S; Liu Z; Thiele CJ; Li Z
    J Exp Clin Cancer Res; 2019 Mar; 38(1):118. PubMed ID: 30850026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines.
    Onisto M; Slongo ML; Gregnanin L; Gastaldi T; Carli M; Rosolen A
    Int J Oncol; 2005 Sep; 27(3):791-8. PubMed ID: 16077930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.
    Ghayad SE; Rammal G; Sarkis O; Basma H; Ghamloush F; Fahs A; Karam M; Harajli M; Rabeh W; Mouawad JE; Zalzali H; Saab R
    Cancer Biol Ther; 2019; 20(3):272-283. PubMed ID: 30307360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells.
    Niesen J; Brehm H; Stein C; Berges N; Pardo A; Fischer R; Ten Haaf A; Gattenlöhner S; Tur MK; Barth S
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):1049-61. PubMed ID: 25433506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.
    van Gaal JC; Roeffen MH; Flucke UE; van der Laak JA; van der Heijden G; de Bont ES; Suurmeijer AJ; Versleijen-Jonkers YM; van der Graaf WT
    Eur J Cancer; 2013 Nov; 49(16):3462-70. PubMed ID: 23867124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of MEF2D expression inhibits differentiation and contributes to oncogenesis in rhabdomyosarcoma cells.
    Zhang M; Truscott J; Davie J
    Mol Cancer; 2013 Nov; 12(1):150. PubMed ID: 24279793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV.
    Pressey JG; Haas MC; Pressey CS; Kelly VM; Parker JN; Gillespie GY; Friedman GK
    Pediatr Blood Cancer; 2013 Jan; 60(1):45-52. PubMed ID: 22408058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors.
    Chadalapaka G; Jutooru I; Sreevalsan S; Pathi S; Kim K; Chen C; Crose L; Linardic C; Safe S
    Int J Cancer; 2013 Feb; 132(4):795-806. PubMed ID: 22815231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular trafficking as a determinant of AS-DACA cytotoxicity in rhabdomyosarcoma cells.
    Wolf SJ; Huynh T; Bryce NS; Hambley TW; Wakelin LP; Stewart BW; Catchpoole DR
    BMC Cell Biol; 2011 Aug; 12():36. PubMed ID: 21861933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic drugs in combination with the CXCR4 antagonist AMD3100 as a potential treatment option for pediatric rhabdomyosarcoma.
    Regenbogen S; Stagno MJ; Schleicher S; Schilbach K; Bösmüller H; Fuchs J; Schmid E; Seitz G
    Int J Oncol; 2020 Jul; 57(1):289-300. PubMed ID: 32377699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells.
    De Salvo M; Raimondi L; Vella S; Adesso L; Ciarapica R; Verginelli F; Pannuti A; Citti A; Boldrini R; Milano GM; Cacchione A; Ferrari A; Collini P; Rosolen A; Bisogno G; Alaggio R; Inserra A; Locatelli M; Stifani S; Screpanti I; Miele L; Locatelli F; Rota R
    PLoS One; 2014; 9(5):e96238. PubMed ID: 24797362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Up-regulation of GLI1 in vincristine-resistant rhabdomyosarcoma and Ewing sarcoma.
    Yoon JW; Lamm M; Chandler C; Iannaccone P; Walterhouse D
    BMC Cancer; 2020 Jun; 20(1):511. PubMed ID: 32493277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells.
    Cassandri M; Pomella S; Rossetti A; Petragnano F; Milazzo L; Vulcano F; Camero S; Codenotti S; Cicchetti F; Maggio R; Festuccia C; Gravina GL; Fanzani A; Megiorni F; Catanoso M; Marchese C; Tombolini V; Locatelli F; Rota R; Marampon F
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma.
    Basma H; Ghayad SE; Rammal G; Mancinelli A; Harajly M; Ghamloush F; Dweik L; El-Eit R; Zalzali H; Rabeh W; Pisano C; Darwiche N; Saab R
    Int J Cancer; 2016 Mar; 138(6):1528-37. PubMed ID: 26453552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LEF1 reduces tumor progression and induces myodifferentiation in a subset of rhabdomyosarcoma.
    Dräger J; Simon-Keller K; Pukrop T; Klemm F; Wilting J; Sticht C; Dittmann K; Schulz M; Leuschner I; Marx A; Hahn H
    Oncotarget; 2017 Jan; 8(2):3259-3273. PubMed ID: 27965462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.